Ticagrelor PCD Pharma Franchise Company
Cafoli Lifecare is a WHO-GMP certified PCD pharma franchise company offering a Ticagrelor range of 3 formulations to distributors, stockists and franchise partners across India. Each product is manufactured at approved facilities, packed for the Indian retail chain and offered with district-level monopoly rights, so the effort you put into building cardiology coverage stays yours.
What is Ticagrelor?
Ticagrelor is an oral antiplatelet drug of the cyclopentyltriazolopyrimidine class. It reversibly binds the P2Y12 receptor on platelets and blocks ADP-mediated platelet activation and aggregation, which reduces the risk of new thrombus forming in a diseased coronary artery. Unlike thienopyridines such as clopidogrel, Ticagrelor is directly active and does not require hepatic CYP2C19 conversion. It is used with low-dose aspirin in acute coronary syndrome and after coronary stenting, and is a prescription-only medicine that must be initiated by a cardiologist or physician. Compound and pharmacology data are available on PubChem.
Ticagrelor Formulations Available with Cafoli Lifecare
The Ticagrelor portfolio comprises 3 formulations, all in tablet form. Complete strength, packing and net-rate details are shared with registered franchise enquiries.
Therapeutic Applications of Ticagrelor
- Acute coronary syndrome — unstable angina, NSTEMI and STEMI, given with aspirin
- Prevention of stent thrombosis after percutaneous coronary intervention (PCI)
- Long-term secondary prevention of atherothrombotic events in selected high-risk patients, at specialist discretion
Core prescribers are cardiologists and interventional cardiologists, supported by emergency physicians, intensivists and CCU teams. Cath-lab hospitals and cardiac centres are the highest-value call points for this molecule.
Why Ticagrelor is a High-Potential Molecule for Distributors
India's cardiac interventional volume has been climbing steadily as cath labs spread beyond metros into tier-2 and tier-3 cities, and every PCI patient leaves hospital on dual antiplatelet therapy. That therapy typically runs for about twelve months, which converts a single hospital admission into a year of repeat retail demand — a rare pattern in the cardiac segment. Ticagrelor is also displacing older antiplatelets in guideline-driven ACS protocols because it is directly active and unaffected by CYP2C19 polymorphism, so the prescription base is growing rather than static. For a distributor, that means a molecule with a rising script curve, a concentrated and easily covered prescriber list, and dependable monthly refills.
Why Choose Cafoli Lifecare for Your Ticagrelor Franchise
- Monopoly rights — one partner per district, territory protected
- WHO-GMP certified manufacturing and DCGI-approved formulations
- Promotional inputs — visual aids, doctor sample packs, literature, reminder gifts and MR bags
- 1000+ franchise partners across India
- On-time despatch, transparent net rates and dedicated order support
References
- PubChem — Ticagrelor compound record, National Library of Medicine
- PubMed — clinical literature on ticagrelor in acute coronary syndrome
- WHO Model List of Essential Medicines
Our formulations of Ticagrelor find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: